Innovent Biologics. has filed a patent for novel antibodies or antigen-binding fragments that specifically bind to CD73. The patent also covers the nucleic acid encoding the antibody, a vector, a host cell, an immunoconjugate, and a pharmaceutical composition. The invention has potential uses in immunotherapy, prevention, and diagnosis of diseases. The patent claim specifies the sequences of the complementarity determining regions of the antibody. GlobalData’s report on Innovent Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innovent Biologics, Nanoparticle drug conjugates was a key innovation area identified from patents. Innovent Biologics's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for an anti-cd73 antibody or antigen-binding fragment
A recently filed patent (Publication Number: US20230312741A1) describes an anti-CD73 antibody or antigen-binding fragment that can be used for various applications in the field of cancer treatment. The patent claims specify the amino acid sequences and regions of the antibody that are important for its binding to CD73.
The patent claims describe different variations of the anti-CD73 antibody or antigen-binding fragment. These variations include specific combinations of complementarity determining regions (CDRs) from the heavy chain variable region and light chain variable region. The amino acid sequences of these CDRs are provided in the patent claims.
The patent claims also mention that the anti-CD73 antibody or antigen-binding fragment can be humanized or fully human, making it suitable for therapeutic use in humans. Additionally, the claims cover different types of antigen-binding fragments, such as Fab, Fab', Fab'-SH, Fv, single chain antibody (scFv), (Fab')2, single domain antibody, diabody (dAbs), camelid antibody, or linear antibody.
The patent claims further describe the use of the anti-CD73 antibody or antigen-binding fragment for the treatment of cancer or tumors, particularly breast cancer, lung cancer, or melanoma. The antibody is claimed to have properties such as high affinity binding to CD73, blocking the enzymatic activity of soluble CD73, and reversing the inhibition of T cell proliferation and activity by AMP-adenosine.
The patent claims also cover methods of preparing the anti-CD73 antibody or antigen-binding fragment, as well as pharmaceutical compositions and immunoconjugates comprising the antibody. The patent claims mention the use of the antibody or antigen-binding fragment in combination with an anti-PD1 antibody, such as sintilimab, for the treatment of cancer or tumors.
Overall, this patent application describes an anti-CD73 antibody or antigen-binding fragment with potential therapeutic applications in cancer treatment. The claims provide detailed information about the amino acid sequences and regions of the antibody, as well as its use in various compositions and methods.
To know more about GlobalData’s detailed insights on Innovent Biologics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
